SG11202102114UA - Anti-klrg1 antibodies - Google Patents

Anti-klrg1 antibodies

Info

Publication number
SG11202102114UA
SG11202102114UA SG11202102114UA SG11202102114UA SG11202102114UA SG 11202102114U A SG11202102114U A SG 11202102114UA SG 11202102114U A SG11202102114U A SG 11202102114UA SG 11202102114U A SG11202102114U A SG 11202102114UA SG 11202102114U A SG11202102114U A SG 11202102114UA
Authority
SG
Singapore
Prior art keywords
klrg1
antibodies
klrg1 antibodies
Prior art date
Application number
SG11202102114UA
Other languages
English (en)
Inventor
Stefano Gulla
Evan Thompson
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of SG11202102114UA publication Critical patent/SG11202102114UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202102114UA 2018-09-17 2019-09-06 Anti-klrg1 antibodies SG11202102114UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732329P 2018-09-17 2018-09-17
PCT/US2019/050110 WO2020060781A1 (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Publications (1)

Publication Number Publication Date
SG11202102114UA true SG11202102114UA (en) 2021-04-29

Family

ID=69887899

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102114UA SG11202102114UA (en) 2018-09-17 2019-09-06 Anti-klrg1 antibodies

Country Status (13)

Country Link
US (1) US20210347899A1 (ko)
EP (1) EP3852779A4 (ko)
JP (1) JP2022501065A (ko)
KR (1) KR20210060477A (ko)
CN (1) CN112752580A (ko)
AU (1) AU2019344524A1 (ko)
BR (1) BR112021004553A2 (ko)
CA (1) CA3113069A1 (ko)
EA (1) EA202190647A1 (ko)
IL (1) IL281594A (ko)
MX (1) MX2021003119A (ko)
SG (1) SG11202102114UA (ko)
WO (1) WO2020060781A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056289A1 (en) * 2020-09-11 2022-03-17 National Jewish Health Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells
MX2023011102A (es) 2021-03-26 2023-11-28 Abcuro Inc Anticuerpos anti-klrg1.
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2024072872A2 (en) * 2022-09-27 2024-04-04 The Brigham And Women's Hospital, Inc. Klrg1 signalling therapy for infectious disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133365B1 (en) * 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
JP6097690B2 (ja) * 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
CN106456766B (zh) * 2014-03-19 2020-03-10 台湾基督长老教会马偕医疗财团法人马偕纪念医院 抗免疫原性糖肽的抗体、包含其的组合物及其用途
EP3471539A4 (en) * 2016-06-03 2020-02-26 The Brigham and Women's Hospital SIGNALING PROCESSING WITH KLRG1
EP3512553A4 (en) * 2016-09-16 2021-01-06 The Brigham and Women's Hospital, Inc. KLRG1 DEPLETION THERAPY

Also Published As

Publication number Publication date
EP3852779A1 (en) 2021-07-28
EA202190647A1 (ru) 2021-09-09
AU2019344524A1 (en) 2021-03-25
JP2022501065A (ja) 2022-01-06
KR20210060477A (ko) 2021-05-26
US20210347899A1 (en) 2021-11-11
EP3852779A4 (en) 2022-06-08
IL281594A (en) 2021-05-31
BR112021004553A2 (pt) 2021-06-08
CA3113069A1 (en) 2020-03-26
MX2021003119A (es) 2021-05-14
WO2020060781A1 (en) 2020-03-26
CN112752580A (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
SG11202106214YA (en) Novel anti-ccr8 antibody
IL280780A (en) Anti-TIGIT antibodies
IL279352A (en) IL-11RA antibodies
GB201709808D0 (en) Antibodies
IL280013A (en) Anti-IL36R antibodies
IL278010A (en) Antibodies to galectin 10
IL289112A (en) Antibodies against tigit
IL277030A (en) Antibodies
GB201707561D0 (en) GARP-TGF-beta antibodies
GB202110263D0 (en) Anti-btla antibodies
IL291068A (en) Anti-cd73 antibodies
ZA202101177B (en) Anti-btla antibody
IL284584A (en) Anti-tigit antibodies
GB201811368D0 (en) Antibody
IL281594A (en) Antibodies against KLRG1
GB201817172D0 (en) Antibody
GB201905150D0 (en) Ant-ige antibodies
GB201806084D0 (en) Antibodies
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
IL289160A (en) Anti-angpt2 antibodies
GB201711785D0 (en) Antibodies
SG11202105718TA (en) Modified antibodies
GB201819952D0 (en) Antibodies